News Agency
Men's Weekly

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

  • Written by PR Newswire

 ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models —

 In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's Investigational New...

Read more: Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a...

How Labour Hire Supports Sydney and Gold Coast Businesses

Labour hire has transformed from a simple stopgap measure into one of the most strategically valuable workforce solutions for businesses right across Sydney and the Gold Coast. As various industries grow, adapt to punishing seasonal demand, or suddenly find themselves... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion